<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809262</url>
  </required_header>
  <id_info>
    <org_study_id>1222.3</org_study_id>
    <nct_id>NCT01809262</nct_id>
  </id_info>
  <brief_title>Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Single Dose Preliminary Dose-ranging and Safety in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To investigate bronchodilator effect and safety of single doses of BI
      1744 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics
      of BI 1744 CL
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1) at 24 hours after a single dose</measure>
    <time_frame>at 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 after a single dose</measure>
    <time_frame>up to 3 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the FEV1 curve till 12 h (FEV1 AUC0-12) after a single dose</measure>
    <time_frame>baseline till 12 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-24h after a single dose</measure>
    <time_frame>baseline till 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC12-24h after a single dose</measure>
    <time_frame>from 12 h till 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-3h after a single dose</measure>
    <time_frame>baseline till 3 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak forced vital capacity (FVC) after a single dose</measure>
    <time_frame>up to 3 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak bronchodilator response after a single dose</measure>
    <time_frame>up to 3 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of response after a single dose</measure>
    <time_frame>up to 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring rescue medication on a test-day after a single dose</measure>
    <time_frame>up to 24 h post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events: during study period onset and end date, causality and intensity of any untoward medical occurrence were recorded</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: blood pressure and heart rate on test-days in conjunction with each lung function test, and at screening and at completion of last test-day (or at withdrawal visit)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECGs: at screening and at completion of last test-day (or at withdrawal visit)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory evaluations (routine blood chemistry, haematology and urinalysis): at screening and at completion of last test-day (or at withdrawal visit)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>olodaterol 2 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 5 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of placebo</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 40 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 40 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 20 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 20 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 2 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 2 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 10 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 10 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Smoking history of more than 10-pack years

        Exclusion criteria:

          1. History of asthma, allergic rhinitis, myocardial infarction or unstable of
             life-threatening cardiac arrhythmias

          2. Marked baseline prolongation of QT/QTc interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.3.1 Atrium medisch centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 8, 2013</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
